CMS Finalizes Higher Medicare Advantage Rates, Easing UnitedHealth's Policy Overhang

What happened

UnitedHealth Group has been mired in Medicare Advantage policy uncertainty, with the proposed CY2027 rate at a concerning +0.09% that management labeled 'far below' medical cost trends. This week, CMS released the final CY2027 Medicare Advantage capitation rates, projecting a 2.48% increase in payments, or effectively about 4.98% when risk score trends are included, significantly above the initial proposal. The higher final rate alleviates the acute funding gap that had pressured UNH's earnings and stock price, directly addressing the binary catalyst highlighted in the DeepValue report. However, UNH's own filings warn of persistent medical cost pressures, planned MA membership contraction in 2026, and Optum Health value-based care losses that remain headwinds. While this update reduces immediate policy risk, the investment case now hinges on whether UNH can manage costs and execute its right-sizing strategy without further adverse developments.

Implication

The final CY2027 MA rate of ~4.98% exceeds the +1.5% threshold that the DeepValue report identified as a bullish catalyst, potentially improving UNH's margin outlook and shifting probabilities toward the base or bull scenarios. This reduces the dominant policy risk that justified a 'WAIT' rating, allowing for a reassessment of the investment thesis with less ambiguity. However, UNH's guidance still includes MA membership contraction, elevated MCR around 88.8% ± 50 bps, and Optum Health VBC losses, meaning the rate benefit must offset ongoing cost pressures. Investors should now focus on quarterly MCR prints to confirm that repricing and benefit adjustments are effectively managing medical trends, as any deviation could reignite downside risks. A cautious stance remains prudent until the second quarter of 2026 provides clarity on cost trends and membership stability, ensuring the rate boost translates into sustainable earnings power.

Thesis delta

The previous thesis centered on a high-stakes wait for the Apr 6 MA rate announcement, with bearish risks if rates stayed near +0.09% and locked in a funding-versus-trend gap. The final rate of ~4.98% materially improves the funding outlook, shifting the dominant driver from policy shock to execution on cost management and membership control. This moves the probability-weighted scenario towards the base or bull case, but the thesis is not fully resolved until MCR trends and Optum Health performance confirm stabilization without further reserve builds.